Item 16. Form 10-K Summary

Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected to not include such summary information.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SOLVENTUM CORPORATION

(Registrant)


Date: February 27, 2026
	By	/s/ Wayde McMillan
		Wayde McMillan,
	Executive Vice President and Chief Financial Officer (Mr. McMillan is the Principal Financial Officer and has been duly authorized to sign on behalf of the Registrant.)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on February 27, 2026.


Signature						Title
/s/ Bryan Hanson						Bryan Hanson, Chief Executive Officer (Principal Executive Officer and Director)
/s/ Wayde McMillan						Wayde McMillan, Executive Vice President, Chief Financial Officer (Principal Financial Officer)
/s/ Mary Wilcox						Mary Wilcox, Senior Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)
/s/Carlos Albán						Carlos Albán, Director
/s/Carrie S. Cox						Carrie S. Cox, Chair of the Board of Directors
/s/Susan D. DeVore						Susan D. DeVore, Director
/s/Shirley Edwards						Shirley Edwards, Director
/s/Glenn A. Eisenberg						Glenn A. Eisenberg, Director
/s/Dr. Bernard A. Harris Jr.						Dr. Bernard A. Harris Jr., Director
/s/Karen J. May						Karen J. May, Director
/s/Elizabeth A. Mily						Elizabeth A. Mily, Director
/s/John H. Weiland						John H. Weiland, Director
/s/Amy A. Wendell						Amy A. Wendell, Director
/s/Darryl L. Wilson						Darryl L. Wilson, Director

Previous: Item 15. Exhibits, Financial Statement Schedules